What a clinical research assistant does day to day, what the role teaches, and how the line to coordinator actually gets drawn. Written for people choosing between the 2 routes.

In this file:

·        Why neither job title exists in any regulation

·        The real line, which is the delegation log and not the title

·        What the assistant role teaches that nothing else does

·        What can and cannot be said about how long people stay

Marcus's name went on the delegation log 5 weeks after he started, next to 3 tasks and a date, initialed by Dr. Reyes.

Nobody made a speech about it. He noticed because Nani printed the updated log, put it in the binder, and said "you can do vitals on your own now." That piece of paper is the single most misunderstood document in site work, and it, rather than anyone's job title, is what actually defines this job.

Here’s the thing worth knowing before you compare 2 job descriptions.

The FDA's regulations recognize exactly 2 roles on a study team. Under 21 CFR 312.3, an investigator is "an individual who actually conducts a clinical investigation," the responsible leader when a team is involved, and a subinvestigator is "any other individual member of that team."

That’s it. "Clinical research coordinator" and "clinical research assistant" appear nowhere in FDA regulation. They’re industry job titles, they mean different things at different sites, and 2 people with the same title at 2 hospitals may be doing substantially different work. They may not even be called the exact same thing at those 2 different hospitals, which is a common theme throughout the industry for a variety of roles.

Which is why comparing the titles is the wrong exercise. Compare the delegation and ask what the role is responsible for at that job.

Every study keeps a list of who’s allowed to do what as required by ICH GCP. In the current version, E6(R3), the investigator "should ensure a record is maintained of the persons and parties to whom the investigator has delegated trial-related activities," and separately must ensure that those people are "appropriately qualified and are adequately informed about relevant aspects of the protocol, the investigational product(s) and their assigned trial activities."

The investigator also keeps the responsibility. R3 is explicit that delegation does not move accountability: the investigator retains ultimate responsibility and must maintain appropriate oversight.

So the practical difference between an assistant and a coordinator, at a given site, is the number of lines next to their name and how consequential those lines are.

A typical early delegation set: consenting no, vitals yes, source documentation yes, drug accountability no, adverse event assessment no, query response yes with review, sample processing yes.

A typical coordinator set: all of the above, plus the consent discussion, plus first pass adverse event capture, plus the relationship with the monitor, plus responsibility for the visit going right at all.

Watch what the added lines have in common. They’re the ones where judgment is being exercised rather than a procedure being performed. That’s the line, and it’s the same line at every site even though the titles are not.

New site staff often believe that only physicians go on Form FDA 1572. That’s not the test.

The FDA's own guidance on the form says the purpose of Section 6 is to capture information about individuals who "will assist the investigator and make a direct and significant contribution to the data," and that in general, if someone is directly involved in performing protocol required procedures and collecting data, that person should be listed.

It goes further and names coordinators specifically: a research coordinator generally has a greater role in performing critical study functions and making direct and significant contributions to the data, and therefore should usually be listed in Section 6.

So the test is what you do, not what you are called. An assistant doing protocol procedures and collecting data may well belong on the form. A senior person whose involvement is administrative may not. Anyone who tells you the rule is about job titles has not read the guidance.

This is the task people assume is the wall between the 2 roles, and it’s more nuanced than that.

The consent discussion can be delegated. FDA's current informed consent guidance, finalized in August 2023, addresses delegation directly: the investigator may delegate the consent discussion to a qualified member of the research team, while the investigator retains responsibility for ensuring consent is obtained properly.

What that means at a site is that consenting is a delegated activity like any other, which appears on the log, and which typically arrives once somebody has watched enough of them and been trained on that specific protocol. It arrives earlier than most new staff expect and it’s a bigger step than most of them realize, because it’s the first task where you are the person a participant is deciding to trust.

Three things, and only one of them is on any job description.

The sequence. An assistant sees the visit from the outside, repeatedly, before being responsible for it. Where the forms live, which lab tube goes with which assay, when the pharmacy needs the call, what the monitor asks for. That pattern recognition cannot be taught in a course and it is what makes a coordinator fast later.

What "adequate and accurate" actually looks like. 21 CFR 312.62(b) requires the investigator to prepare and maintain adequate and accurate case histories recording all observations and data pertinent to the investigation. That sentence means nothing until you’ve watched a monitor read one, and an assistant usually gets to watch that before ever being responsible for one.

The tempo of a site. Some weeks are 2 visits and paperwork. Some weeks are a monitoring visit, a start up, 3 screen failures and an adverse event on the same afternoon. Learning whether that tempo suits you, before you own it, is genuinely valuable information about your own life. And it will vary site by site.

Note to File. Read your delegation log every time it’s reissued, and read your own line. Doing a task you aren’t delegated for is a deviation, and it’s one of the easiest to commit accidentally, because it usually happens when you are trying to be helpful. The other half of that rule matters just as much: if you’ve been doing something for weeks that’s not on your line, the log is wrong and it’s not a small thing. Say so. It’s a 5 minute fix now and a finding later.

Job posts and career pages will tell you a coordinator role follows an assistant role in a tidy number of years. Be careful with that.

There is no national dataset tracking tenure, turnover or progression for clinical research coordinators or research assistants in the US. This issue is not going to invent one. What exists are single institution figures and surveys. Duke, tracking its own clinical research staff from 2016 to 2024, reported voluntary turnover that peaked at about 19 percent in 2021. And a 2021 survey of 85 current and former coordinators across more than 30 US academic medical centers identified the factors people named as driving retention, including the relationship with the principal investigator, compensation, and whether a career advancement pathway existed at all. It reports what people said mattered, with the relationship with the PI at the top. Neither tells you how long a typical person stays before moving up.

So the honest version is this. The move from assistant to coordinator is a delegation decision made by an investigator at a specific site, based on what they have watched you do. It’s not a term of service, and asking in an interview how that decision has been made for the last 2 people who did it is a better question than asking how long it takes.

The FDA's regulations recognize only investigators and subinvestigators, so neither "clinical research assistant" nor "clinical research coordinator" is a regulatory role, and the titles mean different things at different sites. The line that actually matters is the delegation log, which ICH E6(R3) requires the investigator to maintain, along with an obligation to ensure delegated staff are appropriately qualified and informed, and the investigator keeps ultimate responsibility either way. Being listed on Form FDA 1572 turns on function rather than title: the FDA's guidance says anyone making a direct and significant contribution to the data should generally be listed, and that coordinators usually should be. The consent discussion can be delegated to a qualified team member with the investigator retaining responsibility. And there is no reliable published figure for how long anyone stays in either role, so treat any confident number you are given as marketing. Marcus's job changed on the day 3 lines appeared next to his name, and nobody made a speech about it.

Reply to this email or leave a comment on the newsletter: if you started as an assistant, what was the task that made you realize you were already doing coordinator work? Every query gets read, and the best ones get answered in a future issue.

Know someone training for their first coordinator job, or thinking about one? Send them this issue with your own referral link below, so the share counts. The Open Site File is written for exactly that person.

The Open Site File is one part of Root to Rx, and we all work toward the same thing: making clinical research easier to understand and harder to misrepresent. Wednesday, Plain Talk opens in The Root Room, where a real health claim tries to work on someone, then takes it apart in plain language, with the receipts. Sunday, The Roots, on LinkedIn, is a letter for the people whose family treats them as the medical desk. And every Tuesday, The Open Site File shows you the inside of the site, where the people who make trials run actually work. Different doors, one mission: more people who understand how medicine gets made, and fewer people misled about it.

·        Previous issue: Issue 18, what happens when someone leaves a trial early

·        Related: Issue 12, answering a data query

·        For the people whose family treats them as the medical desk: The Roots, our weekly letter.

·        Why the rules read the way they do, and the history behind them: Version History.

·        Helping a patient or family member look for a study? A walkthrough of the public trial registries.

·        Patient materials, including a medication and supplement log modeled on the conmed logs used in trials: shop.roottorx.com.

·        21 CFR 312.3, Definitions, investigator and subinvestigator (eCFR)

·        21 CFR 312.62, Investigator recordkeeping and record retention (eCFR)

·        FDA, Frequently Asked Questions: Statement of Investigator, Form FDA 1572. Information sheet guidance, May 2010

·        FDA, Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors. Final guidance, August 2023

·        ICH E6(R3) Good Clinical Practice, sections 2.3.1 to 2.3.3 on delegation and oversight

·        Buchanan DA, Goldstein J, Pfalzer AC, Lin YC, Kang H, Claassen DO. Empowering the Clinical Research Coordinator in Academic Medical Centers. Mayo Clinic Proceedings: Innovations, Quality and Outcomes. 2021;5(2):265-273

·        Stroo M, Reyes C, Deeter C, Freel SA, Gaudaur H, Sloane R, Snyder DC. Journal of Clinical and Translational Science. 2025;9(1):e134

•  •  •

The Open Site File is general education about how clinical research sites work. It is not regulatory, legal, or medical advice, and it is not tied to any specific study, sponsor, or employer. If you are in a trial, your study team and your own doctor are the right people to ask about your situation. Always follow your own site’s SOPs, your protocol, and your PI and QA team. Names and characters are invented composites.

Disclosure: The Open Site File is part of Root to Rx, published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Filed by Justin Yamashita, MSc., Open Label Media